R
Resurrect Bio
AI-driven gene editing for crop disease resistance
About Resurrect Bio
Resurrect Bio is a UK agricultural biotechnology company that develops disease resistance traits for crops by restoring plants' natural immune defences. The company was spun out of The Sainsbury Laboratory in Norwich in December 2021 and was founded by Sophien Kamoun, Tolga Bozkurt and Cian Duggan, who leads the company as CEO. Its work builds on research into how plant pathogens evolve to suppress the immune receptors that crops use to recognise and fight infection.
The company's approach targets NLR immune receptors in plants. Pathogens secrete effector proteins that bind to these receptors and switch off the plant's immune response. Resurrect Bio identifies these interactions and pinpoints small, precise changes that stop the binding, so that resistance mechanisms already present in elite crop varieties can work again without introducing foreign DNA. The aim is to protect crops against fungal diseases, oomycetes and nematodes with less reliance on chemical crop protection.
Its technology rests on three platforms: FloraFold AI, an in-silico tool trained to predict protein-protein interactions between plant and pathogen proteins; a high-throughput functional biology platform that validates those predictions in the lab and in living plants; and its Resurrection platform, which reactivates cryptic resistance in crop germplasm. Together these are designed to shorten the time from discovery to a trait that can be deployed in crops such as corn, soy and wheat.
Resurrect Bio works with seed companies and plant breeders, developing traits in house and through joint development agreements in which partners carry out the gene edits in their own varieties. It operates from the United Kingdom.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 88.4/100
- Sub-industry
- AgriTech
- Sector
- Biotechnology, Crop Protection, Core AI, Spinout, Sustainable Development Goals, Biotechnology in Food, Climate Tech, DT and LS
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B, B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | May 2026 | $2.2M | $41M | AgFunder · Future Planet Capital · Calculus Capital · Pymwymic | ↗ |
| SERIES AOther financing | Feb 2026 | $8.1M | $32M | Calculus Capital · Corteva · AgFunder · Pymwymic | ↗ |
Growth signals
Latest recorded traffic for Resurrect Bio is 1.4K monthly website visits, down 57.6% over the last three months. Resurrect Bio's team grew 66.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Resurrect Bio in the London ecosystem
The Resurrect Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
SynBioVen
AgFunder
Future Planet Capital
SHAKE Climate Change
UK Research and Innovation
Series A3 investors entered at this stage
Corteva
Calculus Capital
Pymwymic
Other known investors2 additional known investors
The Sainsbury Laboratory
StartLife
Source: Dealroom Talent Intelligence.
See Resurrect Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










